VIDEO TRANSCRIPT + CLOSE -

Mark: Having a community of people that you can discuss your condition with is important because number one, you know, you're not alone. You can only do that when you're talking to people that are actually living with the same condition that you're living.

Onscreen text: Mark was diagnosed with intermediate-risk myelofibrosis (MF) in 2017.

Onscreen text: THE PURPLE CHAIR

EPISODE 5: We Are Not Alone

#InThePurpleChair

Donna: I think other cancers that are much more prevalent, people know the right things to say and the questions to ask you.

Onscreen text: Donna was diagnosed with polycythemia vera (PV) in 2020.

Onscreen text: EVERY JOURNEY WITH A RARE, CHRONIC BLOOD CANCER IS UNIQUE.

Donna: But when you say I have polycythemia vera, they're like, what?

Chuck: The doctor told me it was a very rare condition.

Onscreen text: Chuck was diagnosed with PV in 2014.

Onscreen text: Polycythemia vera (PV) is a rare, chronic blood cancer. In PV, a person’s body makes too many red blood cells (RBCs), white blood cells (WBCs), and platelets.

Donna: I had no one to really talk to.

Chuck: I didn't know really who to turn to for emotional help.

Tami: When I received the MF diagnosis…I was like, OK, I'm going to deal with this, but I want more input. I had nobody to reference.

Onscreen text: Tami was diagnosed with high-risk MF in 2015.

Onscreen text: Myelofibrosis (MF) is a rare, chronic blood cancer of the bone marrow. The bone marrow is the material inside the bone where blood cells are made.

Tami: I had no clue what was going on.

Onscreen text: BUT IT CAN HELP TO HEAR FROM OTHERS WHO HAVE TRAVELED A SIMILAR PATH.

Donna: It's important for us to connect with people. When you have a rare disease…I think you just feel so alone.

Tami: It's different when you talk to somebody who's been there, and you don't feel so orphaned. You don't feel so left out anymore.

Donna: You have your health care team, but they aren't able to provide that emotional support.

Mark: When I'm able to talk to somebody who's experiencing what I'm what I'm going through, it means everything.

Onscreen text: THEIR STORIES CAN INSPIRE AND INFORM.

Donna: The advice I'd give for newly diagnosed patients would be to be a champion for yourself, be aggressive in learning as much as you can about the disease and the treatment options.

Mark: Not missing an appointment…you know, continuing to follow the regimen…

Tami: Keep your eyes open, keep your mind open. Don't just assume that these stats on a computer screen are going to apply directly to you.

Mark: I think more important is making people aware they're not alone.

Tami: That's one of the reasons I wanted to do this. If one person hears this and it helps them, then, hey…I've done a good thing.

Onscreen text: THEIR SUPPORT CAN HELP YOU FIND HOPE.

Tami: MF has opened up…a whole new realm of people for me.

Onscreen text and narrator: Jakafi® (ruxolitinib) is the first FDA-approved prescription medicine for adults with PV who have already taken a medicine called hydroxyurea (HU) and it did not work well enough or they could not tolerate it. Jakafi is also the first FDA-approved prescription medicine for adults with intermediate or high-risk MF.

Onscreen text and narrator: Please see Important Safety Information included in this video and see the Full Prescribing Information for Jakafi.

Donna: When I saw…the phrase Ambassador for Jakafi, the word ambassador really just spoke to my heart.

Onscreen text: Donna has been taking Jakafi since 2020 after she was unable to tolerate hydroxyurea.

Onscreen text: The Ambassadors for Jakafi® (ruxolitinib) program is for eligible patients taking Jakafi who want to share their experiences to help inspire and inform others on their disease and treatment journeys.

Donna: I'm very thankful…that I sit in a purple chair today.

Chuck: The Ambassadors for Jakafi program is important because it's very important for us to help each other out and be an encouragement and a blessing to each other.

Onscreen text: Chuck has been taking Jakafi since 2020 after he was unable to tolerate hydroxyurea.

Donna: We just want you to know we're here.

Mark: I consider myself to be an ambassador. I enjoy sharing my story. I enjoy giving information to people that I think will be beneficial to them.

Onscreen text: Mark has been taking Jakafi for intermediate-risk MF since 2017.

Onscreen text: AND THEIR EXPERIENCES CAN REMIND YOU THAT YOU ARE NOT ALONE.

Chuck: I always look for good in everything, and the way I look at this disease, I can be positive in the fact that I like to help other people.

Tami: Sometimes you can help somebody else. You can give them an answer. And that's the best feeling in the world to be able to help someone who very probably is in the same place you were. And you can see how much it means to me. I’m getting a little teary eyed here.

Onscreen text: Tami has been taking Jakafi for high-risk MF since 2015.

Chuck: Perspective is everything. My disease is serious, but I’ve lived with it for 7 years now.

Onscreen text: This is Chuck's experience with Jakafi. Individual results may vary.

Tami: I'm, you know, what, 11 years into this now.

Onscreen text: This is Tami's experience with Jakafi. Individual results may vary.

Donna: I hope that people who see me and hear me will see…a person who is not defined by her disease.

Donna: …There's a path to possible.

Onscreen text: This is Donna's experience with Jakafi. Individual results may vary.

Onscreen text: WATCH THE FULL SERIES AT Jakafi.com/InThePurpleChair.

Onscreen text: Brought to you by Jakafi® (ruxolitinib)

#InThePurpleChair

Onscreen text and narrator: Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information at Jakafi.com, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Onscreen text: LEARN MORE ABOUT JAKAFI® (ruxolitinib)

#InThePurpleChair

This video is sponsored by Incyte Corporation. Jakafi and the Jakafi logo are registered trademarks of Incyte.

© 2022, Incyte Corporation. MAT-JAK-02978  03/22

EPISODE 5

We Are Not Alone

How can connecting with others help inform the journey ahead? Learn how sharing their stories helped these 4 patients realize that they were not alone and helped them find support on their journeys with rare, chronic blood cancers.

WATCH FROM THE BEGINNING:

Image of Mark from The Purple Chair video

EPISODE 1

How Our Journeys Began

WATCH FROM THE BEGINNING:

Image of Mark from The Purple Chair video

EPISODE 1

How Our Journeys Began

We’re Saving a Seat, Just for You

Your story could help educate and inspire others. Learn how you can join a growing network of Incyte Mentors by becoming an Ambassador for Jakafi.